Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

erest related to the settlement reached with U.S. Attorney's Office.

(8) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(9) To exclude charges related to the acquisition of licensed technology in the oncology field.

(10) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED SALES DETAIL

(In thousands)

(Unaudited)

Three Months Ended

September 30,

2008

United

States Europe Total

Sales:

PROVIGIL $241,366 $17,793 259,159

GABITRIL 12,176 2,337 14,513

CNS 253,542 20,130 273,672

ACTIQ 21,392 14,401 35,793

Generic OTFC 19,569 - 19,569

FENTORA 41,330 - 41,330

AMRIX 20,512 - 20,512

Pain
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013 The Conference Forum ... to Advance Clinical Trials conference taking place on September ... MA. , Disruptive thinkers from Novartis, Pfizer, Eli ... bold approaches to reduce expensive infrastructure, engage patients and ... to be big, or novel, or it must change ...
(Date:5/22/2013)... and NEW ORLEANS , ... in the field of regenerative medicine, presented new data ... from Analysis Group (a leading health economics consultancy) demonstrating ... foot ulcers (DFU) and venous leg ulcers (VLU) place ... results of this research, which reveal annual costs of ...
(Date:5/22/2013)... 22, 2013 Mold remediation could take a ... there is a way to cut down the process' expense. ... latest post the details of a method how to ... Mold could be prevented, My Cleaning Products said. But in ... that a mold remediation must then be promptly implemented as ...
(Date:5/22/2013)... May 22, 2013 A recent study from ... on athletes to find that those who took probiotics were ... results from the study showed that in extreme heat conditions, ... for their adult acne treatment explains what this ... it may help their skin condition. , While researchers ...
Breaking Biology Technology:Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2
... is the first complement inhibitor to be tested ... Potentia Pharmaceuticals, a,privately held biotechnology company developing ... announced today that the Company,will be presenting its ... drug,candidate, POT-4, during the Retina Subspecialty Day at ...
... Oral Contraceptive,for the Prevention of Pregnancy, ... (NYSE: BRL ) today announced that ... approved its subsidiary Duramed Pharmaceuticals, Inc.,s New ... mg/0.02 mg and ethinyl estradiol tablets 0.01 ...
... Initiates Rosetta Green, a Project Which Will Leverage Rosetta Genomics, Proprietary microRNA Technologies and Strong IP ... Range of Plant-Based Applications, The Company has Recently Secured ... Trenches as Certain Milestones are ... Reached, Rosetta has Already Identified microRNAs Correlated With Algal Oil Content ...
Cached Biology Technology:Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 2Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 2FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 3FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 4FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive 5Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 2Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 3Rosetta Genomics Leverages its MicroRNA Platform Technologies to Launch Plant Biotech Initiative 4
(Date:5/22/2013)... a novel technique that can detect molecular variants in ... one of the most important, though time-consuming, processes in ... in Nature , post-doctoral researcher David Patterson, Professor ... the Center for Free-Electron Laser Science (CFEL) in Hamburg, ... fields to identify molecular variants apart, and to determine ...
(Date:5/22/2013)... approach to genetic engineering drastically reduces the time ... bacteria, the workhorses of biotechnology, scientists are reporting. ... , the method paves the way for more ... environmental cleanup and other activities. , Keith Shearwin ... piece of the genetic material DNA into a ...
(Date:5/22/2013)... responsible for legionellosis, an infectious disease that can lead ... has developed a complex method enabling it to camouflage ... these acting against the infectious bacteria. , Research led ... which teams from the National Institute of Health (NIH) ... Barcelona (BSC) have also participated, has described for the ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Mechanism discovered which aids Legionella to camouflage itself in the organism 2
... WALL, N.J., July 14 BIO-key International,Inc. (OTC ... safety and,finger-based biometric identification solutions, today issued the ... in its,businesses, operating trends and stock performance., ... customers, recurring licensing,revenues and an increase in our ...
... Ecological Society of America (ESA) will present societal awards ... meeting in Milwaukee, Wisconsin on Monday, August 4, 2008. ... Michael Rosenzweig of the University of Arizona is the ... a senior ecologist in recognition of an outstanding body ...
... WASHINGTON, D.C. The forests of the future may need ... clean water as any other goal, researchers say in a ... offer no "quick fix" to the insatiable, often conflicting demands ... is evolving, scientists say, as both urban and agricultural demands ...
Cached Biology News:BIO-key(R) Issues Open Letter to Shareholders 2BIO-key(R) Issues Open Letter to Shareholders 3BIO-key(R) Issues Open Letter to Shareholders 4BIO-key(R) Issues Open Letter to Shareholders 5Ecological Society of America announces 2008 award recipients 2Ecological Society of America announces 2008 award recipients 3Ecological Society of America announces 2008 award recipients 4New report: Greatest value of forests is sustainable water supply 2New report: Greatest value of forests is sustainable water supply 3
...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
... The IITC Life Science Rotarods are used ... motor coordination or fatigue resistance on mice and ... humane way. Extremely user friendly; the animals are ... an animal drops onto the individual sensing platforms ...
... 8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) is ... (8-iso PGF2α), in rabbits, monkeys and ... product of non-specific lipid peroxidation. In ... 8-isoprostane is converted primarily to metabolites ...
Biology Products: